Article

 

Effectiveness of UNAIDS targets and HIV vaccination across 127 countries Public Deposited

Analytics

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/rb68xh59m

Descriptions

Attribute NameValues
Creator
Abstract
  • The HIV pandemic continues to impose enormous morbidity, mortality and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis. We developed a mathematical model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of diagnosis, treatment, and viral suppression in 127 countries. Under status quo interventions, we predict a median of 49 million [1st and 3rd quartiles 44M, 58M] incident cases globally from 2015 to 2035. Achieving the UNAIDS 95–95–95 target was estimated to avert 25 million [20M, 33M] of these new infections, and an additional 6.3 million [4.8M, 8.7M] reduction was projected with the 2020 introduction of a 50%-efficacy vaccine gradually scaled up to 70% coverage. This added benefit of prevention through vaccination motivates imminent and ongoing clinical trials of viable candidates to realize the goal of HIV control.
Resource Type
Date Available
Date Issued
Academic Affiliation
Subject
Rights Statement
Funding Statement (additional comments about funding)
  • J.M. was supported by National Institutes of Health U01 GM070694. A.P. was supported by a Brown CoxePostdoctoral Fellowship in the Medical Sciences. A.S.P. and A.P.G. were supported by National Institutes of Health U01 GM15627 and National Institutes of Health U01 GM087719. A.T. was supported by a Yale College Dean’s Research Fellowship. L.A.S. was supported by National Institutes of Health T32 AI007404.5
Peer Reviewed
Replaces
Additional Information
  • description.provenance : Submitted by Open Access (openaccess@library.oregonstate.edu) on 2017-03-15T18:00:06Z No. of bitstreams: 2 Effectiveness_of_HIV_vaccine_final.pdf: 961418 bytes, checksum: ad36c1eecba0c9dc426016a94380f928 (MD5) supporting_information.pdf: 11817801 bytes, checksum: 7a4b51bb6caf0b6c4e9f56d802bc18e7 (MD5)
  • description.provenance : Made available in DSpace on 2017-03-20T20:47:58Z (GMT). No. of bitstreams: 3 medlockj2051261764.zip: 12301076 bytes, checksum: 08f28daed51216c7181c7d5a42d344bf (MD5) Effectiveness_of_HIV_vaccine_final.pdf: 961418 bytes, checksum: ad36c1eecba0c9dc426016a94380f928 (MD5) supporting_information.pdf: 11817801 bytes, checksum: 7a4b51bb6caf0b6c4e9f56d802bc18e7 (MD5)
  • description.provenance : Approved for entry into archive by Steven Van Tuyl(steve.vantuyl@oregonstate.edu) on 2017-03-20T20:47:58Z (GMT) No. of bitstreams: 3 medlockj2051261764.zip: 12301076 bytes, checksum: 08f28daed51216c7181c7d5a42d344bf (MD5) Effectiveness_of_HIV_vaccine_final.pdf: 961418 bytes, checksum: ad36c1eecba0c9dc426016a94380f928 (MD5) supporting_information.pdf: 11817801 bytes, checksum: 7a4b51bb6caf0b6c4e9f56d802bc18e7 (MD5)

Relationships

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
Effectiveness_of_HIV_vaccine_final.pdf 11/16/2017 Public
supporting_information.pdf 11/16/2017 Public